MediciNova Achieves a Major Milestone with MN-166
MediciNova, Inc., located in La Jolla, California, has recently reached an important milestone that paves the way for advancements in the treatment of neurodegenerative diseases. The company announced that an abstract related to its clinical trial of MN-166, also known as ibudilast, has been accepted for presentation at the upcoming Annual NEALS Meeting. This event will gather experts in amyotrophic lateral sclerosis (ALS), giving MediciNova a valuable opportunity to present its cutting-edge research.
Overview of the COMBAT-ALS Clinical Trial
The COMBAT-ALS Phase 2b/3 trial of MN-166 is a vital study designed to assess the efficacy and safety of this medication in patients suffering from ALS. The details of the trial will be presented in a poster format on October 23, 2024, by Dr. Björn Oskarsson, an important contributor to this research and an Associate Professor of Neurology. This presentation highlights MediciNova's dedication to improving treatment options for ALS patients.
Details of the Presentation
The accepted abstract will address key components of the trial. Here are some important details:
- Submission ID: 164
- Title: COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Study Design and Trial Update
- Session: Poster Presentation
- Date: October 23, 2024
Exploring MN-166 (Ibudilast)
MN-166 is a small molecule compound recognized for its function as a phosphodiesterase type-4 (PDE4) inhibitor, along with its capacity to modulate inflammatory cytokines. This drug is currently in late-stage clinical development not just for ALS, but also for various other conditions including progressive multiple sclerosis, degenerative cervical myelopathy, glioblastoma, and long COVID. Its diverse mechanisms of action position it as a promising candidate in the field of neurodegenerative therapies.
About MediciNova, Inc.
MediciNova is committed to creating innovative therapies that target inflammatory, fibrotic, and neurodegenerative conditions. The company has a broad pipeline of clinical programs, led by its primary compound, MN-166, which is advancing through Phase 3 trials aimed at both ALS and degenerative cervical myelopathy. Additionally, MN-001 (tipelukast) is included in their pipeline and is currently being developed for metabolic-associated fatty liver disease.
With a robust foundation in clinical research, MediciNova is well-equipped to drive multiple initiatives that have the potential for significant impact. Their unwavering focus on patient care and innovative scientific approaches continues to propel the company's achievements.
Frequently Asked Questions
What is the significance of the NEALS meeting?
The NEALS meeting is a prestigious event that showcases the latest research in ALS and related areas, providing a platform for experts to exchange findings and advancements.
What is MN-166 used for?
MN-166 is primarily being studied for its effects on neurodegenerative diseases, including ALS, progressive multiple sclerosis, and other related conditions.
Who is presenting the MN-166 abstract?
The abstract regarding the MN-166 clinical trial will be presented by Dr. Björn Oskarsson, a distinguished Associate Professor of Neurology.
What stage is MN-166 currently in for ALS treatment?
MN-166 is currently undergoing Phase 3 clinical trials for ALS, indicating that it has made significant progress in its development.
Where can I learn more about MediciNova?
To find more information about MediciNova, including their initiatives and contact details, you can visit their official website or reach out via email.